Effects of intravenous butorphanol on cardiopulmonary function in isoflurane-anesthetized alpacas.

Vet Anaesth Analg

Veterinary Teaching Hospital, Department of Veterinary Clinical Sciences, College of Veterinary Medicine, Washington State University, Pullman, WA, USA.

Published: July 2007


Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Objective: To determine the effects of intravenous (IV) butorphanol on the cardiopulmonary system and on the bispectral index (BIS) in isoflurane-anesthetized alpacas.

Study Design: Randomized, blinded cross-over experimental trial.

Animals: Eight healthy, young (3 +/- 1 SD years) adult female alpacas weighing 64 +/- 9 SD kg.

Methods: Alpacas were anesthetized with isoflurane by mask followed by tracheal intubation and maintenance of anesthesia with isoflurane in oxygen and intermittent positive pressure ventilation. Animals were assigned to two treatments, butorphanol (0.1 mg kg(-1), IV) and saline (0.01 mL kg(-1), IV) in a randomized manner allowing a 2-week interval between treatments. Cardiovascular variables included systolic, diastolic, and mean arterial blood pressure, heart rate, pulmonary arterial pressure, pulmonary arterial occlusion pressure (PAOP), central venous pressure, cardiac output, and pulmonary temperature (TEMP). Cardiac index, systemic vascular resistance (SVR), and pulmonary vascular resistance (PVR) were calculated. Bispectral index was also measured. Arterial and mixed venous blood samples were collected for blood gas analysis. All variables were recorded at baseline (time 0) and at 5, 10, 15, 30, 45 and 60 minutes following injection and were analyzed by using repeated-measures ANOVA (p < 0.05). PAOP, PVR, and BIS were analyzed by paired t-tests.

Results: Butorphanol decreased SVR at all times when compared with the baseline, but no difference was detected between treatments. TEMP decreased with time in both treatments, but they were not different from each other. Other cardiovascular, BIS, and blood gas variables were not different between groups.

Conclusion And Clinical Relevance: We conclude that butorphanol had minimal effects on the cardiovascular system of the alpacas, causing a mild decrease in SVR.

Download full-text PDF

Source
http://dx.doi.org/10.1111/j.1467-2995.2006.00325.xDOI Listing

Publication Analysis

Top Keywords

effects intravenous
8
intravenous butorphanol
8
butorphanol cardiopulmonary
8
treatments cardiovascular
8
pulmonary arterial
8
vascular resistance
8
blood gas
8
butorphanol
5
pressure
5
cardiopulmonary function
4

Similar Publications

Objective: Cisplatin-induced acute kidney injury (Cis-AKI) is a significant cause of renal damage, characterized by tubular injury, ferroptosis, and oxidative stress. While therapeutic options for Cis-AKI remain limited, identifying novel targets to prevent kidney injury is critical. This study focuses on GALNT14, a gene associated with ferroptosis, and its potential role in mitigating Cis-AKI.

View Article and Find Full Text PDF

Ketamine and Esketamine for Late-Life Depression: A Systematic Review of Efficacy, Safety, and Tolerability.

Am J Geriatr Psychiatry

August 2025

Mood Disorder and Psychopharmacology Unit (RS, JKT, CED, RSM), University Health Network, Toronto, Ontario, Canada; Department of Psychiatry, University of Toronnto, Toronto, ON, Canada; Department of Pharmacology and Toxicology, University of Toronto, ON, Canada. Electronic address: roger.mcintyre@

Ketamine has emerged as a promising treatment for major depression, though its efficacy and safety remain incompletely characterized in older adults. This systematic review synthesizes current evidence for ketamine in geriatric depression. A search of PubMed, EMBASE, and PsycINFO was conducted.

View Article and Find Full Text PDF

Saikosaponin A (SSa) is an oleanane type triterpenoid saponin isolated from Radix Bupleuri (Bupleurum chinense DC). While SSa has demonstrated significant pharmacological activities including anti-inflammatory, antioxidant, and antidepressant effects, its pharmacokinetic profile remains poorly characterized. This study developed and validated a sensitive LC-MS/MS method for quantifying SSa in rat plasma.

View Article and Find Full Text PDF

Fahr's syndrome is a rare neurological condition marked by unusual calcifications in the basal ganglia and other brain regions, often resulting from metabolic disorders, such as hypoparathyroidism. Secondary hypoparathyroidism, a frequent complication of total thyroidectomy, can lead to Fahr's syndrome, manifesting as movement disorders, seizures, psychiatric symptoms and indications of calcium deficiency. This case report discusses a woman in her mid-30s who developed Fahr's syndrome due to secondary hypoparathyroidism after total thyroidectomy.

View Article and Find Full Text PDF

Subcutaneous Opioids: Under the Skin Irritation or New Standard of Care?

J Pain Symptom Manage

September 2025

Department of Palliative Medicine, OhioHealth Riverside Methodist Hospital, Columbus, Ohio (Beachy, Aung, Malone, Petros, Bertke); Department of Pharmacy, OhioHealth Riverside Methodist Hospital, Columbus, Ohio (Durell, Tressel).

Background: Opioids are widely used for pain management in hospitalized adults and can be administered through various routes. While oral (PO) and intravenous (IV) routes remain most common, the subcutaneous (SUB-Q) route is underutilized despite historical safety and supporting literature.

Objective: This quality improvement study implemented a revised standard of practice (SOP) for opioid administration, promoting the PO route when feasible and SUB-Q as the preferred parenteral route.

View Article and Find Full Text PDF